CD8A and neoplasm: Chen et al. 42 proposed a novel therapeutic regimen that combined αPD-L1 immunotherapy with peptide-based targeted radionuclide therapy and confirmed that this combination therapy can stimulate the infiltration of CD8+ T cells in the tumor microenvironment.